SC
BOLT icon

Shay Capital’s Bolt Biotherapeutics BOLT Stock Holding History

Shay Capital’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.4K Buy
15,438
+533
+4% +$2.5K ﹤0.01% 465
2026
Q1 		$60.2K Sell
14,905
-367
-2% -$1.91K 0.01% 453
2025
Q4 		$83.5K Sell
15,272
-686
-4% -$3.68K 0.01% 453
2025
Q3 		$84.9K Buy
+15,958
New +$88.5K 0.01% 387

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shay Capital's BOLT Position: Q2 2026 in Review

Shay Capital increased its Bolt Biotherapeutics (BOLT) stake by 3.6% in Q2 2026, buying an estimated $2.5K and bringing the position to 15,438 shares worth $59.4K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

Shay Capital first reported a position in BOLT in Q3 2025 and has held it in 4 quarters since. The position peaked at $84.9K in Q3 2025. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Shay Capital held 15,438 shares of Bolt Biotherapeutics worth $59.4K as of Q2 2026.
  • Shay Capital bought 533 Bolt Biotherapeutics shares in Q2 2026, an estimated $2.5K.
  • Bolt Biotherapeutics made up ﹤0.01% of Shay Capital's portfolio in Q2 2026, its #465 holding.
  • Shay Capital first reported a position in Bolt Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • Shay Capital's Bolt Biotherapeutics position peaked at $84.9K in Q3 2025.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.